Skip to main content

CRISPR gene editing to take on inherited blindness in U.S. study

A new study in the United States will use CRISPR gene-editing technology to treat Leber congenital amaurosis (LCA), a retinal condition that is a major cause of inherited blindness. The study, which will take place later in 2019, is currently open for would-be patients to enroll.

LCA affects roughly one in 80,000 people, making it the most common form of inherited sight loss among children. The condition causes the light-sensing photoreceptor cells at the back of the eye to stop functioning correctly. Symptoms can involve poor peripheral vision, night blindness, and faulty pupil reactions. Over time, these conditions can worsen; leaving patients able to only detect the faint outlines of shapes or even totally blind.

The test will evaluate a gene therapy named AGN-151587 as a treatment for LCA. The study will assess safety, tolerability, and efficacy of this treatment in 18 patients. Patients in the study will receive a single dose of AGN-151587 administered using a subretinal injection in the eye.

“We are very proud of our continued commitment to developing innovative treatments for unmet needs in eye care,” David Nicholson, Chief R&D Officer at Allergan, said in a statement. “Beginning patient enrollment in the AGN-151587 clinical trial with our partners at Editas is an important step toward our goal of developing a game-changing, transformative, CRISPR-based medicine for people with LCA10.”

This is a significant advance in the usage of CRISPR gene-editing technology. Since bursting onto the scene a decade ago, CRISPR has opened up a slew of new possibilities — from the creation of malaria-resistant mosquitoes to, as this study could help confirm, life-changing medical advances. CRISPR got a bad rap last year when it was used as part of a controversial Chinese experiment in which gene-editing was used on embryos or infants. Unlike that widely condemned experiment, this work involves fully grown consenting adults.

“Now that enrollment is underway, we are one step closer to delivering a transformative medicine to LCA10 patients,” Charles Albright, Chief Scientific Officer of Editas Medicine, one of the other companies involved with the study, said in a press statement. “The team at Editas looks forward to continuing to collaborate with our partners at Allergan, patient advocacy organizations, and the inherited retinal diseases community as we develop this and other durable experimental medicines for patients with devastating ocular diseases.”

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
U.S. astronaut shares highs and lows of record space trip
NASA astronaut Mark Vande Hei aboard the space station.

NASA astronaut Mark Vande Hei is returning to Earth this week after setting a new record for the longest continuous spaceflight by an American.

On March 15, Vande Hei broke the existing 340-day record set by Scott Kelly in 2016, and when he leaves the International Space Station (ISS) in the next few days, that record will have extended to 355 days, just 10 short of a full year.

Read more
Watch NASA’s U.S. weather satellite rocket launch highlights
watch highlights of rocket launch us weather satellite noaa

The National Oceanic and Atmospheric Administration’s (NOAA) new weather satellite successfully launched from NASA's Cape Canaveral facility in Florida at 4:38 p.m. ET (1:38 p.m. PT) on Tuesday, March 1.

Watch NOAA's GOES-T Weather Satellite Launch to Geostationary Orbit

Read more
Rocket Lab selects U.S. site to launch, land next-gen rocket
Rocket Lab's Neutron rocket.

Rocket Lab highlighted its growing ambitions as a spaceflight company this week when it announced NASA’s Wallops Flight Facility in Virginia as the launch site for upcoming missions that will use its next-generation Neutron rocket.

Rocket Lab said it will also build Neutron at Wallops and use the location to prepare and conduct Neutron missions.

Read more